Facebook Pixel Medical devices need separate regulatory framework | Bio Spectrum – Business – Lesen Sie diese Geschichte auf Magzter.com
Mit Magzter GOLD unbegrenztes Potenzial nutzen

Mit Magzter GOLD unbegrenztes Potenzial nutzen

Erhalten Sie unbegrenzten Zugriff auf über 9.000 Zeitschriften, Zeitungen und Premium-Artikel für nur

$149.99
 
$74.99/Jahr

Versuchen GOLD - Frei

Medical devices need separate regulatory framework

Bio Spectrum

|

Decemeber 2019

Medical devices need separate regulatory framework

Medical devices need separate regulatory framework

The vast majority of India’s medical devices of which is nearly 80 per cent import-dependent, are unregulated for quality and safety. While many of these products may have regulatory certifications in other countries, the reality is that a considerable number of them are being exported from countries that do not regulate their exports. The medical devices market in India is over $15 billion (Rs 105,000 crore) and projected to grow to $50 billion by 2025 and is the fourth-largest in Asia.

Thirty years have gone by since the 1st medical device was regulated as a drug in 1989. A comprehensive regulatory framework is nearly in sight with the Draft MEDICAL DEVICES (Safety, Effectiveness & Innovation) Bill from NITI Aayog to be shortly proposed as a Separate Law.

Our policymakers in Health Ministry were surprisingly undecided and seemed to be in no urgency to usher in a ‘Patient Safety Medical Devices Law to protect patients, even after the recent ICIJ implant files or J&J incident, or the most recent ban on Transvaginal Pelvic Mesh by US Food and Drug (FDA). As Ministry of Health & Family Welfare (MoHFW) had been surprisingly very reluctant to draft a separate law preferring to attempt to amend the Drugs Act and Central Drugs Standard Control Organization (CDSCO) has a conflict of interest to empower itself the industry watchers are waiting with anxiety the details of the Draft Medical Devices Bill that NITI Aayog is reportedly working upon in consultation with other stakeholder departments and ministries to address the regulatory vacuum & the national patient safety concerns.

WEITERE GESCHICHTEN VON Bio Spectrum

Bio Spectrum

Bio Spectrum

Can India's CDMOS Lead the Next Biopharma Wave?

India's Contract, Development, and Manufacturing Organisation (CDMO) sector is projected to grow from $3-3.5 billion today to $22-25 billion by 2035, noted Boston Consulting Group (BCG).

time to read

8 mins

March 2026

Bio Spectrum

Bio Spectrum

Telangana turns catalyst for innovation

Telangana is at a pivotal moment in its journey as a global life sciences hub.

time to read

6 mins

March 2026

Bio Spectrum

Bio Spectrum

Is AI the New Weapon in the Fight to End TB?

A report released at the India AI Impact Summit 2026, organised by the Government of India, reveals that artificial intelligence (AI) is being successfully deployed at scale across India’s public healthcare system to address the growing burden of tuberculosis (TB).

time to read

2 mins

March 2026

Bio Spectrum

Bio Spectrum

ChemWerth on-boards Chandrakanth Reddy as new GSM to increase generic API footprint in India

US-based ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its position in the Indian market.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

Beyond the Glass Ceiling: Women-Led Companies Shaping India's Health Economy

Over the past decade, women entrepreneurs have gained strong ground in India's healthcare sector, building ventures in diagnostics, FemTech, biotech, and care delivery.

time to read

5 mins

March 2026

Bio Spectrum

Bio Spectrum

"There needs to be a collaborative effort between innovators and policymakers to create frameworks that ensure safety without stifling progress"

Started in 2021, Decode Age, one of the pioneers in Longevity Research in India, entered its next phase of growth following its Pre-Series A funding round, led by Granules India.

time to read

5 mins

March 2026

Bio Spectrum

Bio Spectrum

Rainbow Children's Medicare appoints Abrarali Dalal as Chief Executive Officer

Rainbow Children's Medicare, a leading provider of paediatrics, perinatal, and women's healthcare services in India, has announced the appointment of Abrarali Dalal as Chief Executive Officer, effective from January 20, 2026.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

Haleon ropes in Kedar Lele as President for India Subcontinent

Haleon, a British multinational consumer healthcare company has announced the appointment of Kedar Lele as President for India Subcontinent (ISC), effective January 2026.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

Centre revises Startup Recognition Framework to strengthen Startup India Action Plan

The government of India has revamped the Startup Recognition Framework to further strengthen the Startup India Action Plan and take forward the Prime Minister's vision of positioning India as a global innovation powerhouse, manufacturing-led economy and hub for emerging tech.

time to read

1 min

March 2026

Bio Spectrum

Bio Spectrum

"In the coming 5 years from now, no Indian CROS will grow or survive without the use of AI"

In January 2026, Ahmedabad-based Veeda Lifesciences announced a strategic leadership transition that marks a new chapter in the company's evolution.

time to read

5 mins

March 2026

Translate

Share

-
+

Change font size